Cullinan's CLN-049 Secures FDA Orphan Drug Designation for Relapsed/Refractory AML
CGEM has more than doubled off its 52-week low of $5.68 on elevated volume (2.2× avg).
Summary
Cullinan Therapeutics announced that its investigational FLT3xCD3 T cell engager, CLN-049, has received FDA Orphan Drug Designation for relapsed/refractory Acute Myeloid Leukemia (AML). This designation provides significant development incentives, including tax credits, user fee exemptions, and potential seven years of market exclusivity upon approval, which de-risks the development pathway for CLN-049. This positive regulatory milestone for a pipeline asset is important, especially following the company's recent Q1 2026 report which indicated a significantly reduced cash runway. Investors will now monitor the progress of CLN-049 through its ongoing Phase 1 studies and look for further clinical data readouts.
At the time of this announcement, CGEM was trading at $15.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $913.9M. The 52-week trading range was $5.68 to $16.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.